(NASDAQ:SSKN) HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204.
Related Questions
How will the $2.42 million direct offering affect STRATA’s existing share dilution and earnings per share?
What is the intended use of the net proceeds and how might that influence STRATA’s growth trajectory or upcoming product milestones?
Will the recent offering create upward or downward pressure on the stock’s price in the short term, considering the size of the issuance relative to daily average volume?